FDA aka Murder Inc. goes full out against the tykes
For some time now we have known that the CDC protocol for Covid patients in hospitals is Remdesivir. Remdesivir, you may recall, is an experimental drug developed to treat Ebola. It was found not only ineffective, it did not alleviate the conditions caused by the Ebola virus, but actually harmful in that it degraded kidney function. Consequently it was withdrawn from use.
Remdesivir was developed by the pharmaceutical company Gilead Sciences, Inc. Loath to simply lose the money invested in the project and given that the US Congress has absolved pharmaceutical companies from liability for injuries caused by, shall we say, less than effective medications, Gilead Sciences looked around for another situation in which they could sell Remdesivir. Enter the WuFlu, Covid 19.
The FDA granted Gilead Sciences an Emergency Use Authorization to use Remdesivir in hospitals for adults suffering from Covid 19. At the same time the FDA prohibited effective treatments such as Hydroxychloroquine, Ivermectin and others, mandating Remdesivir as the ONLY approved protocol for treating Covid 19 in hospitalized adults. As Remdesivir is a very expensive drug, about $3,000 for one course of treatment, it is no surprise that hospitals spend more money on Remdesivir than on all other drugs combined.
All patients are tested for Covid using the PCR test (which has a 95% false positive rate) even before admission. If found Covid positive treatment is mandatory and the Covid protocols are initiated, more on that in the video below. Kidney function is impaired, water retention naturally follows, the lungs begin to accumulate fluid, entubation is then necessary and ultimately the
victim patient dies and the hospital collects $37,000 from the government plus all the other costs of hospitalization. In New York this had been turned into such a profitable system that a mass production line was created to keep it going.
Not content with these massive profits, the FDA has been persuaded to extend the EUA for Remdesivir to outpatient adults and children.
The agency also revised the emergency use authorization for remdesivir to authorize the drug for treatment of pediatric patients weighing between 3.5 kg and less than 40 kg, or pediatric patients less than 12 years of age weighing at least 3.5 kg, with positive results of direct SARS-CoV-2 viral testing, and who are not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.
Yes! Now even newborns, toddlers, infants and pre-teens can share in the benefits of Remdesivir, even though they are the population least affected by Covid. Needless to say the primary benefit being the enrichment of Gilead Sciences, Inc., but not neglecting the CDC and the FDA who hold Remdesivir connected patents, nor the politicians who turn a blind eye to the whole ghastly practice.
Here’s Dr. Sherri Tenpenny with more.